More interestingly, an IHC analysis using TMAs to analyze the expression of six EMT biomarkers (FSCN1, cortactin, survivin, EGFR, MMP-2, and MMP-9) in serous carcinomas, mucinous carcinomas, endometrioid adenocarcinomas, and clear cell carcinomas found significant expression of only FSCN1, cortactin, survivin, and EGFR [138]. This evidence concerns the gene FSCN1 and serous adenocarcinoma.